MA-CLS-2 Cells

The MA-CLS-2 cell line was established from the pleural effusion of a female patient diagnosed with breast ductal carcinoma. This cell line originates from a human breast tumor and specifically represents a pleural metastasis, which is often associated with advanced stages of cancer. The original tumor was classified as pT1 NO GII, indicating a primary tumor of limited size (T1), with no regional lymph node metastasis (N0), and graded as moderately differentiated (GII). These characteristics suggest that the tumor was relatively early-stage but had already disseminated to the pleural cavity, a complication that significantly impacts patient prognosis.
MA-CLS-2 is particularly valuable for studying the metastatic processes of breast cancer, especially those involving pleural effusion, which can provide insights into the mechanisms of tumor spread and potential therapeutic targets. The cell line offers a model to investigate the interactions between metastatic breast cancer cells and the pleural environment, facilitating research into novel interventions aimed at preventing or treating metastatic disease. As a model of a pleural metastasis derived from a ductal carcinoma, MA-CLS-2 also allows for the examination of drug responses in the context of metastatic breast cancer.